Filing summary
Company and period: The filing identifies the registrant as NantKwest, Inc., not ImmunityBio, Inc. It is a Form 10-K for the fiscal year ended December 31, 2017; the filing also provides unaudited fourth-quarter results, but is not a standalone quarterly filing.
Business context
NantKwest describes itself as a clinical-stage immunotherapy company developing natural killer (NK) cell therapies for cancer, infectious diseases, and inflammatory diseases. Its pipeline includes aNK, antibody-enhanced haNK, antigen-targeted taNK, and combined t-haNK candidates. The company had no approved therapeutic products and generated no product-sales revenue. Its strategy relied on advancing clinical trials, developing manufacturing capacity, and pursuing combinations with vaccines, antibodies, and other agents.
Financial performance and position
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Revenue | $45,000 | $44,000 |
| Research and development expense | $42.0 million | $29.2 million |
| Selling, general and administrative expense | $57.1 million | $95.4 million |
| Total operating expenses | $99.2 million | $124.5 million |
| Operating loss | $99.1 million | $124.5 million |
| Net loss | $96.4 million | $120.8 million |
| Net loss per share, basic and diluted | $1.20 | $1.47 |
| Operating cash used | $48.8 million | $38.6 million |
Revenue was immaterial, so the filing does not present a meaningful operating margin. Gross margin is not clearly applicable or reported for this pre-revenue business. FY 2017 net loss improved by $24.4 million, while operating loss improved by $25.4 million. The decline in SG&A chiefly reflected lower stock-based compensation; R&D rose with clinical, laboratory, manufacturing, and personnel activity.
At year-end, cash and cash equivalents were $23.9 million and marketable securities were $133.9 million, down from $8.1 million and $278.4 million, respectively, in 2016. Working capital was $111.6 million, versus $192.6 million. Total assets were $250.4 million; total liabilities were $31.6 million; stockholders’ equity was $218.8 million. The filing reports lease and financing obligations rather than presenting a simple conventional-debt headline: minimum lease payments totaled $21.3 million, including $4.1 million due within one year. The company paid $19.9 million of financing/capital lease principal during 2017.
Cash increased by $15.8 million during 2017, primarily as marketable securities matured or were sold; operating activities used $48.8 million, investing activities provided $99.6 million, and financing activities used $35.0 million. Capital spending for property and equipment was $34.8 million. The company repurchased 3.6 million shares for $15.2 million during the year.
Unaudited fourth-quarter 2017 revenue was $12,000, operating loss was $25.4 million, and net loss was $24.5 million, or $0.31 per share. Fourth-quarter 2016 revenue was $14,000 and net loss was $24.2 million, or $0.29 per share.
Changes, outlook, and material items
- R&D expense increased $12.9 million year over year as the company expanded clinical and manufacturing work. SG&A expense fell $38.3 million, mainly because stock-based compensation expense decreased by $36.1 million.
- Management said available cash, cash equivalents, and marketable securities were expected to fund operations and capital expenditures for at least 12 months, based on assumptions that could prove inaccurate. The company expected substantial ongoing losses and no significant product revenue for several years, if ever, and anticipated needing additional financing.
- Clinical progress included FDA clearance of multiple haNK combination-trial INDs and early-stage studies in several cancer types. Management reported preliminary observations in a small number of pancreatic-cancer patients; these were not established efficacy results. HER2.taNK’s first patient was dosed in a European study, with no adverse events reported at that time.
- The company opened a pilot cGMP manufacturing site and was completing a larger El Segundo facility. It reported frozen haNK shelf stability of more than six months, while commercial-scale production and the taNK freezing/thawing process remained development risks.
- Material risks include clinical and regulatory uncertainty, manufacturing scale-up and supply dependence, competition, intellectual-property challenges, and the possibility of further capital needs and shareholder dilution. A securities class action related to prior interim financial-statement restatements remained pending; management could not estimate a loss range. The company also disclosed derivative litigation and a patent-related dispute with the USPTO.
- Related-party arrangements were significant, including shared services, facilities, and clinical work involving entities affiliated with the CEO. The CEO and affiliated entities held approximately 59.2% of outstanding shares at year-end. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Confirm the issuer identity and reporting period: the supplied filing is NantKwest’s FY 2017 10-K, despite the ImmunityBio metadata and “2017 Q4” period label.
- Review the audited statements and liquidity assumptions, including the split between cash and marketable securities, operating cash use, committed lease payments, and the timing of potential financing needs.
- Check subsequent clinical-trial enrollment, safety, and controlled efficacy data; distinguish preliminary company commentary from trial results sufficient to support approval.
- Track manufacturing-facility completion, regulatory qualification, reproducible product yields, and taNK cryopreservation and distribution readiness.
- Assess developments in the securities and derivative litigation, the USPTO matter and patent opposition, and the financial and governance implications of related-party arrangements and concentrated ownership.